Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: Results of an open-label, randomized, controlled trial

Drugs and Aging

Volumn 30, Issue 5, 2013, Pages 309-319

  Dbaibo, Ghassan ^a   El Ayoubi, Nabil ^a   Ghanem, Soha ^a   Hajar, Farah ^a   Bianco, Veronique ^b   Miller, Jacqueline M ^c   Mesaros, Narcisa ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b GSK   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD GROUP TYPING; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VACCINATION;

EID: 84876904143     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0065-0     Document Type: Article

References (45)

1. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23(12 Suppl):S274-279. (Pubitemid 44544509)
2. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-91.
3. Australian Meningococcal Surveillance Programme. Australian Meningococcal Surveillance Programme annual report, 2010. Commun Dis Intell. 2011;35(3):217-28.
4. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(7):887-96. (Pubitemid 43974695)
5. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;24(27 Suppl 2):B51-63.
6. Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis. 2002;185(5):618-26. (Pubitemid 34171466)
7. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657-63.
8. Decosas J, Koama J-BT. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis. 2002;2(12):763-5. (Pubitemid 35434562)
9. Collard JM, Maman Z, Yacouba H, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis. 2010;16(9):1496-8.
10. Memish ZA, Goubeaud A, Bröker M, et al. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3(4):143-51.
11. Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36(6):679-83. (Pubitemid 36337970)
12. Aguilera J-F, Perrocheau A, Meffre C, et al. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761-7.
13. Parent du Chatelet I, Barboza P, Taha M. W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. Euro Surveill. 2012;17(21):1-2.
14. Saudi Ministry of Health Requirements - Hajj. 2012 Jan 9 [online]. Available from URL: http://www.hajinformation.com/main/p3001.htm.
15. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142-64. (Pubitemid 43157651)
16. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307-22.
17. Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178(3):870-4. (Pubitemid 28397241)
18. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745-52. (Pubitemid 44902007)
19. Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851-61.
20. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM (197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010;14(10):e868-75.
21. Dbaibo G, Macalalad N, Reyes MRA-DL, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012;8(7):873-80.
22. Reyes MRA-DL, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8 (7):881-7.
23. Nimenrix. Meningococcal group A, C, W 135 and Y conjugate vaccine. European Medicines Agency. 2012. 2012 Jun 22 [online]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002226/human-med-001548.jsp&mid=WC0b01ac058001d124.
24. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009;27(1):161-8.
25. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28(3):744-53.
26. Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30(3):e41-8.
27. Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29(25):4274-84.
28. Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30(4):e56-62.
29. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with InfanrixTM hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29(25):4264-73.
30. Bermal N, Huang L-M, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccine. 2011;7(2):239-47.
31. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4(2):156-67. (Pubitemid 27130227)
32. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23(17-18):2222-7. (Pubitemid 40341456)
33. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780-6. (Pubitemid 37129487)
34. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11(2):137-44. (Pubitemid 13053038)
35. Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol. 2004;11(1):83-8. (Pubitemid 38090656)
36. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907-13. (Pubitemid 41423328)
37. Al-Mazrou Y, Khalil M, Findlow H, et al. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccine: phase III, controlled, randomized, modified blind-observer study. Clin Vaccine Immunol. 2012;19(7):999-1004.
38. Dbaibo G, Van der Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 2012;16(8):e608-6.
39. United Nations Population Division. World population prospects: the 2010 revisions population database. 2011 [online]. Available from: http://esa.un.org/unpd/wpp/unpp/panel-indicators.htm.
40. Dagan R, Poolman J, Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513-23.
41. Karabay O, Ozkardes F, Tamer A, Karaarslan K. Tetanus immunity in nursing home residents of Bolu, Turkey. BMC Public Health. 2005;12(5):5. (Pubitemid 40300833)
42. Redwan E-RM, Al-Awady MK. Prevalence of tetanus immunity in the Egyptian population. Hum Antibodies. 2002;11(1-2):55-9. (Pubitemid 35024879)
43. Cilla G, Sáenz-Domínguez JR, Montes M, Part C, Pérez-Trallero E. Immunity against tetanus in adults over the age of 49 years. Med Clin. 1994;103(15):571-3.
44. Theeten H, Rümke H, Hoppener FJP, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin. 2007;23(11):2729-39. (Pubitemid 350146410)
45. Van Damme P, McIntyre P, Grimprel E, et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine. 2011;29(35):5932-9.